Amylin stimulates fatty acid esterification in 3T3-L1 adipocytes

Molecular and Cellular Endocrinology

Volumn 366, Issue 1, 2013, Pages 99-107

  Miegueu, Pierre ^a   St Pierre, David H ^b   Munkonda, Mercedes Nancy ^a   Lapointe, Marc ^a   Cianflone, Katherine ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Adipocyte differentiation; Fatty acid uptake; Insulin; Lipolysis; Pancreatic hormone

Indexed keywords

AMYLIN; CALCITONIN RECEPTOR; CCAAT ENHANCER BINDING PROTEIN BETA; CD36 ANTIGEN; DIACYLGLYCEROL ACYLTRANSFERASE 1; FATTY ACID; FATTY ACID BINDING PROTEIN 4; INSULIN; KERATINOCYTE DERIVED CHEMOKINE; MESSENGER RNA; MONOCLONAL ANTIBODY KI 67; MONOCYTE CHEMOTACTIC PROTEIN 1; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; SOMATOMEDIN C; THYMIDINE; TRIACYLGLYCEROL;

ADIPOCYTE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCITONIN RECEPTOR GENE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; ESTERIFICATION; FATTY ACID ESTERIFICATION; FATTY ACID TRANSPORT; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIPID STORAGE; LIPOLYSIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROADIPOCYTE; RECEPTOR ACTIVITY MODIFYING PROTEIN 3 GENE; RECEPTOR GENE;

3T3-L1 CELLS; ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BIOLOGICAL TRANSPORT; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; ESTERIFICATION; FATTY ACIDS; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; GLUCOSE; GLYCEROL; HUMANS; INSULIN; ISLET AMYLOID POLYPEPTIDE; MICE; MITOCHONDRIA; RECEPTORS, ISLET AMYLOID POLYPEPTIDE; RNA, MESSENGER;

EID: 84872489617     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.12.008     Document Type: Article

References (51)

1. Bailey R., Walker C.S., Ferner A.H., Loomes K.M., Prijic G., Halim A., Whiting L., Phillips A.R., Hay D.L. Pharmacological characterisation of rat amylin receptors: implications for the identification of amylin receptor subtypes. Br. J. Pharmacol. 2011.
2. Butler P., Chou J., Carter W.B., Wang Y.N., Bu B.H., Chang D., Rizza R.A. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990, 39:752-756.
3. Chavez M., Kaiyala K., Madden L.J., Schwartz M.W., Woods S.C. Intraventricular insulin and the level of maintained body weight in rats. Behav. Neurosci. 1995, 109:528-531.
4. Christopoulos G., Perry K.J., Morfis M., Tilakaratne N., Gao Y., Fraser N.J., Main M.J., Foord S.M., Sexton P.M. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol. Pharmacol. 1999, 56:235-242.
5. Cornish J., Callon K.E., Cooper G.J., Reid I.R. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem. Biophys. Res. Commun. 1995, 207:133-139.
6. Cornish J., Callon K.E., King A.R., Cooper G.J., Reid I.R. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am. J. Physiol. 1998, 275:E694-E699.
7. Enoki S., Mitsukawa T., Takemura J., Nakazato M., Aburaya J., Matsukara.S., Toshimori H. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 1992, 15:97-102.
8. Hanabusa T., Kubo K., Oki C., Nakano Y., Okai K., Sanke T., Nanjo K. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 1992, 15:89-96.
9. Hay D., Christopoulos G., Christopoulos A., Poyner D.R., Sexton P.M. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol. Pharmacol. 2005, 67:1655-1665.
10. Heptulla R., Rodriguez L.M., Bomgaars L., Haymond M.W. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 2005, 54:1100-1107.
11. Hou X., Sun L., Li Z., Mou H., Yu Z., Li H., Jiang P., Yu D., Wu H., Ye X., Lin X., Le Y. Associations of amylin with inflammatory markers and metabolic syndrome in apparently healthy Chinese. PLoS One 2011, 6:e24815.
12. Huml M., Kobr J., Siala K., Varvarovská J., Pomahacová R., Karlíková M., Sýkora J. Gut peptide hormones and pediatric type 1 diabetes mellitus. Physiol. Res. 2011, 60:647-658.
13. Isaksson B., Wang F., Permert J., Olsson M., Fruin B., Herrington M.K., Enochsson L., Erlanson-Albertsson C., Arnelo U. Chronically administered islet amyloid polypeptide in rats serves as an adiposity inhibitor and regulates energy homeostasis. Pancreatology 2005, 5:29-36.
14. Kobelt P., Goebel M., Stengel A., Schmidtmann M., van der Voort I.R., Tebbe J.J., Veh R.W., Klapp B.F., Wiedenmann B., Wang L., Taché Y., Mönnikes H. Bombesin, but not amylin, blocks the orexigenic effect of peripheral ghrelin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291:R903-R913.
15. Kuwasako K., Cao Y.N., Nagoshi Y., Tsuruda T., Kitamura K., Eto T. Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins. Mol. Pharmacol. 2004, 65:207-213.
16. Leckström A., Lundquist I., Ma Z., Westermark P. Islet amyloid polypeptide and insulin relationship in a longitudinal study of the genetically obese (ob/ob) mouse. Pancreas 1999, 18:266-273.
17. Leuthauser K., Gujer R., Aldecoa A., McKinney R.A., Muff R., Fischer J.A., Born W. Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition. Biochem. J. 2000, 351(Pt 2):347-351.
18. Lutz T. Amylinergic control of food intake. Physiol. Behav. 2006, 89:465-471.
19. Lutz T. The role of amylin in the control of energy homeostasis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 298:R1475-R1484.
20. Lutz T. Control of energy homeostasis by amylin. Cell. Mol. Life Sci. 2012, 69:1947-1965.
21. Lutz T., Geary N., Szabady M.M., Del Prete E., Scharrer E. Amylin decreases meal size in rats. Physiol. Behav. 1995, 58:1197-1202.
22. Mack C., Wilson J., Athanacio J., Reynolds J., Laugero K., Guss S., Vu C., Roth J., Parkes D. Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R1855-R1863.
23. MacLaren R., Cui W., Simard S., Cianflone K. Influence of obesity and insulin sensitivity on insulin signaling genes in human omental and subcutaneous adipose tissue. J. Lipid Res. 2008, 49:308-323.
24. MacLaren R., Cui W., Lu H., Simard S., Cianflone K. Association of adipocyte genes with ASP expression: a microarray analysis of subcutaneous and omental adipose tissue in morbidly obese subjects. BMC Med. Genomics 2010, 3:3.
25. Martin L., Siliart B., Lutz T.A., Biourge V., Nguyen P., Dumon H.J. Postprandial response of plasma insulin, amylin and acylated ghrelin to various test meals in lean and obese cats. Br. J. Nutr. 2010, 103:1610-1619.
26. Miegueu P., Cianflone K., Richard D., St-Pierre D. Motilin stimulates preadipocyte proliferation and differentiation and adipocyte lipid storage. AJP Endo. 2011, 301:E758-E766.
27. Mitsukawa T., Takemura J., Asai J., Nakazato M., Kangawa K., Matsuo H., Matsukura S. Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes 1990, 39:639-642.
28. Moon H., Chamberland J.P., Diakopoulos K.N., Fiorenza C.G., Ziemke F., Schneider B., Mantzoros C.S. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans. Diab. Care 2011, 34:132-138.
29. Moore C., Cooper G.J. Co-secretion of amylin and insulin from cultured islet betacells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem. Biophys. Res. Commun. 1991, 179:1-9.
30. Moreno P., Acitores A., Gutiérrez-Rojas I., Nuche-Berenguer B., El Assar M., Rodriguez-Mañas L., Gomis R., Valverde I., Visa M., Malaisse W.J., Novials A., González N., Villanueva-Peñacarrillo M.L. Amylin effect in extrapancreatic tissues participating in glucose homeostasis, in normal, insulin-resistant and type 2 diabetic state. Peptides 2011, 32:2077-2085.
31. Muff R., Buhlmann N., Fischer J.A., Born W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 1999, 140:2924-2927.
32. Nagae T., Mukoyama M., Sugawara A., Mori K., Yahata K., Kasahara M., Suganami T., Makino H., Fujinaga Y., Yoshioka T., Tanaka I., Nakao K. Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin/CGRP receptor: cloning and upregulation in obstructive nephropathy. Biochem. Biophys. Res. Commun. 2000, 270:89-93.
33. Ogawa A., Harris V., McCorkle S.K., Unger R.H., Luskey K.L. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J. Clin. Invest. 1990, 85:973-976.
34. Osaka T., Tsukamoto A., Koyama Y., Inoue S. Central and peripheral administration of amylin induces energy expenditure in anesthetized rats. Peptides 2008, 29:1028-1035.
35. Pieber T., Roitelman J., Lee Y., Luskey K.L., Stein D.T. Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity. Am. J. Physiol. Endocrinol. Metab. 1994, 267:E156-E164.
36. Qi D., Cai K., Wang O., Li Z., Chen J., Deng B., Qian L., Le Y. Fatty acids induce amylin expression and secretion by pancreatic beta-cells. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E99-E107.
37. Ravussin E., Smith S.R., Mitchell J.A., Shringarpure R., Shan K., Maier H., Koda J.E., Weyer C. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009, 17:1736-1743.
38. Reinehr T., de Sousa G., Niklowitz P., Roth C.L. Amylin and its relation to insulin and lipids in obese children before and after weight loss. Obesity 2007, 15:2006-2011.
39. Roth J., Hughes H., Kendall E., Baron A.D., Anderson C.M. Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 2006, 147:5855-5864.
40. Roth J., Roland B.L., Cole R.L., Trevaskis J.L., Weyer C., Koda J.E., Anderson C.M., Parkes D.G., Baron A.D. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl. Acad. Sci. USA 2008, 105:7257-7262.
41. Rushing P., Hagan M.M., Seeley R.J., Lutz T.A., Woods S.C. Amylin: a novel action in the brain to reduce body weight. Endocrinology 2000, 141:850-853.
42. van Hulst K., Nieuwenhuis M.G., Höppener J.W., Lips C.J., Blankenstein M.A. Lack of islet amyloid polypeptide/amylin-immunoreactivity in urine collected from healthy volunteers after ingestion of a carbohydrate-rich meal. Exp. Clin. Endocrinol. Diabetes 1996, 104:177-179.
43. Wen Y., Wang H., MacLaren R., Wu J., Lu H., Cianflone K. Palmitate and oleate induction of acylation stimulating protein resistance in 3T3-L1 adipocytes and preadipocytes. J. Cell Biochem. 2008, 104:391-401.
44. Weyer C., Fineman M.S., Strobel S., Shen L., Data J., Kolterman O.G., Sylvestri M.F. Properties of pramlintide and insulin upon mixing. Am. J. Health Syst. Pharm. 2005, 62:816-822.
45. Wielinga P., Alder B., Lutz T.A. The acute effect of amylin and salmon calcitonin on energy expenditure. Physiol. Behav. 2007, 91:212-217.
46. Wielinga P., Löwenstein C., Muff S., Munz M., Woods S.C., Lutz T.A. Central amylin acts as an adiposity signal to control body weight and energy expenditure. Physiol. Behav. 2010, 101:45-52.
47. Woods S. Signals that influence food intake and body weight. Physiol. Behav. 2005, 86:709-716.
48. Wookey P., Tikellis C., Nobes M., Casley D., Cooper M.E., Darby I.A. Amylin as a growth factor during fetal and postnatal development of the rat kidney. Kidney Int. 1998, 53:25-30.
49. Young A. Amylin and the integrated control of nutrient influx 2005, vol. 52. Academic Press, pp. 67-77.
50. Young A. Inhibition of Insulin Secretion 2005, vol. 52. Academic Press, pp. 173-192.
51. Zhang Z., Liu X., Morgan D.A., Kuburas A., Thedens D.R., Russo A.F., Rahmouni K. Neuronal receptor activity-modifying protein 1 promotes energy expenditure in mice. Diabetes 2011, 60:1063-1071.